Lindsey Shapiro, PhD,  —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Using Soliris for PNH lowers blood clot, mortality risk: Study

Soliris (eculizumab) treatment was associated with a nearly 50% reduction in mortality risk and a 60% lower risk of blood clots or other major blood vessel-related events in people with paroxysmal nocturnal hemoglobinuria (PNH), according to data from a global registry study. Those having the greatest survival benefits…

FDA clears injector aiming to make Empaveli use more convenient

The U.S. Food and Drug Administration (FDA) has cleared for use an injector device intended to make self-administration of Empaveli (pegcetacoplan) more convenient for adults with paroxysmal nocturnal hemoglobinuria (PNH). Empaveli, marketed as Aspaveli in Europe, is given via under-the-skin (subcutaneous) injections. Before the FDA decision, patients were…

Empaveli injection-site reactions decline over time: Trial data

Long-term treatment with Empaveli (pegcetacoplan) was generally well tolerated among adults with paroxysmal nocturnal hemoglobinuria (PNH), with the rate of injection-site reactions declining over time. That’s according to data from the Phase 3 PEGASUS clinical trial (NCT03500549) and the open-label extension (OLE) Study 307 (NCT03531255) that spanned…